These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8056688)

  • 1. Structure-activity and structure-side-effect relationships for the quinolone antibacterials.
    Domagala JM
    J Antimicrob Chemother; 1994 Apr; 33(4):685-706. PubMed ID: 8056688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
    Domagala JM; Bridges AJ; Culbertson TP; Gambino L; Hagen SE; Karrick G; Porter K; Sanchez JP; Sesnie JA; Spense FG
    J Med Chem; 1991 Mar; 34(3):1142-54. PubMed ID: 1848296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of chemical structure on quinolone potency, spectrum and side effects.
    Percival A
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():1-8. PubMed ID: 1787126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Amino-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6,8-difluoro-1,4- dihydro-4-oxo-3-quinolinecarboxylic acid (PD 124,816). Synthesis and biological evaluation of a new class of quinolone antibacterials.
    Domagala JM; Hagen SE; Hutt MP; Sanchez JP; Sesnie J; Trehan AK
    Drugs Exp Clin Res; 1988; 14(7):453-60. PubMed ID: 2853667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel fluoroquinolone antibacterial agents containing oxime-substituted (aminomethyl)pyrrolidines: synthesis and antibacterial activity of 7-(4-(aminomethyl)-3-(methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6- fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (LB20304).
    Hong CY; Kim YK; Chang JH; Kim SH; Choi H; Nam DH; Kim YZ; Kwak JH
    J Med Chem; 1997 Oct; 40(22):3584-93. PubMed ID: 9357525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1- pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy.
    Domagala JM; Hagen SE; Joannides T; Kiely JS; Laborde E; Schroeder MC; Sesnie JA; Shapiro MA; Suto MJ; Vanderroest S
    J Med Chem; 1993 Apr; 36(7):871-82. PubMed ID: 8385225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.
    De Sarro A; De Sarro G
    Curr Med Chem; 2001 Mar; 8(4):371-84. PubMed ID: 11172695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinolone antimicrobial agents: structure-activity relationships.
    Zhang MQ; Haemers A
    Pharmazie; 1991 Oct; 46(10):687-700. PubMed ID: 1803382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolone antibacterials. An update of their pharmacology and therapeutic use.
    von Rosenstiel N; Adam D
    Drugs; 1994 Jun; 47(6):872-901. PubMed ID: 7521829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of quinolones against mycobacteria.
    Jacobs MR
    Drugs; 1995; 49 Suppl 2():67-75. PubMed ID: 8549419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1995 Dec; 48(12):1891-8. PubMed ID: 8587163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interactions with quinolone antibacterials.
    Brouwers JR
    Drug Saf; 1992; 7(4):268-81. PubMed ID: 1524699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.
    Peterson LR
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S180-6. PubMed ID: 11524717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756).
    Hayashi K; Takahata M; Kawamura Y; Todo Y
    Arzneimittelforschung; 2002; 52(12):903-13. PubMed ID: 12572531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fluoroquinolone antibacterial agents.
    Rosen T
    Prog Med Chem; 1990; 27():235-95. PubMed ID: 2217826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
    Suto MJ; Domagala JM; Roland GE; Mailloux GB; Cohen MA
    J Med Chem; 1992 Dec; 35(25):4745-50. PubMed ID: 1469702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fluoroquinolones.
    Walker RC
    Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicities.
    Siporin C
    Annu Rev Microbiol; 1989; 43():601-27. PubMed ID: 2679364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2.
    Fuhr U; Strobl G; Manaut F; Anders EM; Sörgel F; Lopez-de-Brinas E; Chu DT; Pernet AG; Mahr G; Sanz F
    Mol Pharmacol; 1993 Feb; 43(2):191-9. PubMed ID: 8429824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.